-
2024-513959-33-00
4
2025-05-13
Asthma
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2024-515162-13-00
5
2025-04-29
Eosinophilic Asthma
-
2023-504904-26-00
5
2025-04-07
Progressive Pulmonary Fibrosis
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2023-508307-21-00
5
2025-03-19
Prader-Willi syndrome
-
2023-509853-29-00
10
2025-02-24
amyotrophic lateral sclerosis
-
2024-517504-11-00
5
2025-01-29
Pregnant patients diagnosed with premature rupture of membranes (PROM)
-
2024-511945-20-00
4
2025-01-24
patients affected by small cell lung cancer (SCLC)
-
2024-516450-21-00
6
2024-12-31
metastatic or locally advanced urothelial cancer
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2024-519286-21-00
5
2024-12-17
MALIGNANT PLEURAL MESOTHELIOMA PATIENTS
-
2022-500455-23-00
5
2024-12-11
Candidemia
-
2024-518092-62-00
5
2024-12-09
Adult critically ill patients requiring non-invasive (NIMV) or invasiv
-
2024-512053-24-00
4
2024-12-05
recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSC
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2024-517863-22-00
5
2024-12-01
Study population consists in patients with a diagnosis of mCRC who hav
-
2023-508949-40-00
4
2024-11-29
Eosinophilic esophagitis
-
2023-508191-11-00
5
2024-11-28
Systemic lupus erythematosus (SLE)
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-512895-36-00
5
2024-11-25
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2024-516466-11-00
4
2024-11-12
Locally advanced or metastatic pancreatic neoplasm with pathogenetic (
-
2024-516591-15-00
6
2024-11-12
urinary tract infections